Digestive System Disorders Clinical Trial
Official title:
A Randomised, Double-blind, Placebo-controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort in Healthy Subjects
Digestive discomfort includes gastrointestinal symptoms such as abdominal pain, altered
bowel habit, flatulence and bloating and can sometimes result from slower intestinal transit
and other digestive irregularities.
The objective of this study is to investigate the effect of consuming Aquamin (as AquaCal
and AquaPT) on digestive discomfort and symptoms amongst adults without diagnosed
gastrointestinal disorders.
Digestive discomfort includes gastrointestinal symptoms such as abdominal pain, altered
bowel habit, flatulence and bloating and can sometimes result from slower intestinal transit
and other digestive irregularities. Digestive discomfort may lead to health issues in the
long-term. In a recent survey of over 1,000 women in the UK, 88% reported having experienced
digestive discomfort from time to time, but the majority of them (70%) had never consulted a
doctor or nurse. Digestive discomfort is often a source of embarrassment for people; they
therefore may be reluctant to address these issues with a healthcare professional.
Aquamin is a seaweed-derived mineral source, which is rich in calcium, magnesium and 74
other trace minerals including zinc, iron and selenium. It is produced from the red algae,
Lithothamnion Calcareum, which is found in just three locations in the world, including the
south-west coast of Ireland and Iceland. During a five-year life span, these algae absorb
essential minerals from the sea - this gives Aquamin its unique multimineral content. The
algae then break down naturally and settle on the sea bed. These calcified skeletal remains
are harvested, washed, dried and milled and provided in a capsule formulation. Aquamin is
proven to deliver digestive health benefits. In a recent study, mice feed on a high-fat
'Western-style' diet (HFWD) and Aquamin, suppressed colon polyp formation and a reduction in
systemic inflammatory changes in comparison to those not receiving Aquamin.
The objective of this study is to investigate the effect of consuming Aquamin (as AquaCal
and AquaPT) on digestive discomfort and symptoms amongst adults without diagnosed
gastrointestinal disorders.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01405612 -
Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01405599 -
Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects
|
Phase 1 | |
| Unknown status |
NCT01318928 -
The Treatment of Periodontal Diseases
|
Phase 4 | |
| Completed |
NCT01304394 -
Safety During Use of Paediatric Triple Chamber Bag Formulas
|
Phase 3 | |
| Completed |
NCT01485328 -
Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics
|
Phase 3 |